PMID- 29466690
OWN - NLM
STAT- MEDLINE
DCOM- 20180927
LR  - 20180927
IS  - 1944-7930 (Electronic)
IS  - 1539-6509 (Linking)
VI  - 25
IP  - 135
DP  - 2018 Jan
TI  - Safety and efficacy of etanercept-methotrexate combination therapy in patients 
      with rhupus: an observational study of non-glucocorticoid treatment for rheumatic 
      diseases.
PG  - 14-20
AB  - OBJECTIVES: To evaluate the safety and efficacy of etanercept (ETN) plus 
      methotrexate (MTX) in patients with rhupus without using corticosteroids. 
      METHODS: Twenty rhupus patients [meeting the criteria for both rheumatoid 
      arthritis (RA) and systemic lupus erythematosus (SLE)] who had never been treated 
      with corticosteroids, DMARDs, or biological agents with a 28-joint Disease 
      Activity Score (DAS28) >3.2 and lupus nephritis determined from histopathological 
      specimens were enrolled. All patients were treated with MTX plus ETN, and 
      monitored for 24 weeks of treatment. Clinical efficacy was evaluated using the 
      DAS28 and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). 
      Demographic characteristics, clinical parameters, and treatment data were 
      analyzed at baseline (BL) and after 4, 8, 16, and 24 weeks of treatment. The 
      incidence of adverse events (AEs) was evaluated. RESULTS: The 20 patients had a 
      mean age of 44.3+/-8 years and a disease duration of 5.4+/-3.1 years. At week 24, 
      treatment with ETN plus MTX resulted in a significant improvement in DAS28 
      (3.3+/-0.1 vs. 6.0+/-0.1 /BL; p<0.001), tender joint count (2.9+/-0.2 vs. 10.75+/-0.8/BL; 
      p<0.001), swollen joint count (2.7+/-0.2 vs. 8.5+/-0.5/BL; p<0.001), Visual Analog 
      Scale for pain (27.0+/-2.6 mm vs. 66.5+/-3.1 mm/BL; p<0.001), and SLEDAI-2K 
      (6.30+/-0.36 vs. 13.7+/-0.48/BL; p<0.001). During the study, the most frequent AEs 
      were upper respiratory tract infections (10%), injection site reactions (10%), 
      and cutaneous rashes (5%); there were no serious AEs. No deaths, malignancies, or 
      tuberculosis or other serious infections were reported. CONCLUSION: Without 
      corticosteroids, combination therapy of ETN plus MTX was relatively safe and 
      effective in rhupus patients, which indicates efficacy of non-corticosteroid 
      treatment for rhupus.
FAU - Yang, Bei-Bei
AU  - Yang BB
AD  - Department of Dermatology, Second Affiliated Hospital, Zhejiang University School 
      of Medicine, Hangzhou, Zhejiang 310009, China.
AD  - These authors contributed equally to this article.
FAU - Xiao, Hua
AU  - Xiao H
AD  - Department of Rheumatology, the First People's Hospital of Chenzhou, Chenzhou, 
      Hunan 423000, China.
AD  - These authors contributed equally to this article.
FAU - Li, Xiao-Jie
AU  - Li XJ
AD  - Department of Rheumatology, the First People's Hospital of Chenzhou, Chenzhou, 
      Hunan 423000, China.
FAU - Zheng, Min
AU  - Zheng M
AD  - Department of Dermatology, Second Affiliated Hospital, Zhejiang University School 
      of Medicine, Hangzhou, Zhejiang 310009, China.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PL  - United States
TA  - Discov Med
JT  - Discovery medicine
JID - 101250006
RN  - OP401G7OJC (Etanercept)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Drug Therapy, Combination
MH  - Etanercept/*administration & dosage/adverse effects
MH  - Female
MH  - Humans
MH  - Lupus Erythematosus, Systemic/complications/*drug therapy/pathology
MH  - Male
MH  - Methotrexate/*administration & dosage/adverse effects
MH  - Middle Aged
MH  - Rheumatic Fever/complications/*drug therapy/pathology
EDAT- 2018/02/22 06:00
MHDA- 2018/09/28 06:00
CRDT- 2018/02/22 06:00
PHST- 2018/02/22 06:00 [entrez]
PHST- 2018/02/22 06:00 [pubmed]
PHST- 2018/09/28 06:00 [medline]
PST - ppublish
SO  - Discov Med. 2018 Jan;25(135):14-20.